Announced
Completed
Financials
Sources
Tags
Completed
Cross Border
Biotechnology
Venture Capital
Private Equity
Minority
Single Bidder
Friendly
biotechnology company
Acquisition
Denmark
Private
Synopsis
Access Biotechnology led a $135m Series B round in Hemab, a clinical-stage biotechnology company, with participation from Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, Maj Invest Equity, Novo Holdings, RA Capital Management, and HealthCap. "Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need," Benny Sorensen, Hemab CEO and President.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.